Reported 3 days ago
Loomis Sayles' Q1 2025 investor letter highlighted Novartis AG (NVS) as a leading diversified global healthcare company excelling in branded pharmaceuticals across various treatment areas. Following the spinoff of its generics division, Novartis now focuses on innovative medicines, which make up a significant portion of its revenue. The company's shares have shown growth, though it is not among the top picks of hedge funds. Despite this, Novartis remains recognized for its market leadership in important therapeutic areas.
Source: YAHOO